COVID-19 is still Spreading! What Now? - Geert Vanden Bossche looks forward
Joined with Dr Rob Rennebohm
Watch full video on Streamyard >
Geert Vanden Bossche spoke out in early 2021 about the risks of driving viral variants by vaccinating in an pandemic.
His predictions have been mostly accurate so far. Stay ahead of the science by listening to our next discussion.
Geert Vanden Bossche PhD, is an internationally recognised vaccine developer having worked as the head of the Vaccine Development Office at the German Centre for Infection Research. Coordinated Global Alliance for Vaccines and Immunisation's Ebola Vaccine Program and contributed to the implementation of an integrated vaccine work plan in collaboration with Global Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA) and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine candidates.
Joined by Dr Rob Rennebohm, a pediatrician and pediatric rheumatologist. He is currently largely retired. In 2018 he officially retired from the pediatric rheumatology department at Cleveland Clinic, where he was also the Director of the International Susac Syndrome Consultation Service.
Timecodes:
0:00 Intro
2:53 Meet Geert Vanden Bossche
5:25 Meet Dr Rob Rennebohm
8:34 Why did the medical community not ask questions?
14:35 Where does Geert think will happen next?
20:34 Rob summarises
23:17 How does Geert define the risk?
29:17 Why is this not occurring with other viruses?
37:30 What does this mean for the unvaccinated?
40:18 When will the scientific community ask the difficult questions?
45:10 Why have others not reached out to Geert?
51:55 Final thoughts from Rob
54:40 Final thoughts from Geert
Vejon COVID-19 Review is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
My question is when a variant appears in somebody's body that is able to escape the protection in the lungs provided by the non-neutralizing antibodies, will that variant become dominant also in the upper respiratory? I imagine that new variant might simply migrate into the lungs and blood where older variants struggle to go, but the upper respiratory might continue to be dominated by older variants. Thus that infected person will mostly spread the older variants to other people even though his lungs and blood are infected with the new variant.
This seems to be a missing step in Geert's proof that I wish could be clarified for laypeople like me.
EDIT: I think my question is answered at the 27 minute mark in the video. Geert says non-neutralizing antibodies serve two purposes - viral clearance and protection in the lungs. The viral clearance is the new area of competition between variants, and that has the side effect of increasing virulence in the lungs.
Looking forward to this.